Earnings ·
Xenetic Biosciences reported financial results for the quarter ended June 30, 2026
XBIOXenetic Biosciences, Inc.
Xenetic Biosciences reported financial results for the quarter ended June 30, 2026. Royalty revenue increased approximately 12% to $0.7 million, while research and development expenses decreased 16% to $0.6 million. General and administrative expenses rose 64% to $1.1 million due to legal costs associated with a strategic review process. The company reported a net loss of approximately $0.9 million compared to $0.7 million in the prior year period. Cash and cash equivalents stood at $6.5 million as of June 30, 2026. Highlights include positive preclinical data presented at ASCO regarding DNase I enhancing CAR T-cell therapy outcomes and regulatory approval for an investigator-initiated study by partner PeriNess Ltd. Xenetic Biosciences is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers.